Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure-Response Analysis.

Autor: Yoshihara K; Quantitative Clinical Pharmacology, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Kobayashi Y; Quantitative Clinical Pharmacology, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Endo S; Quantitative Clinical Pharmacology, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Fukae M; Quantitative Clinical Pharmacology, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Hennig S; Certara Inc., Melbourne, Australia., Kastrissios H; Certara Inc., Melbourne, Australia.; QuanTx Consulting, Mountain View, CA, USA., Kamiyama E; Quantitative Clinical Pharmacology, Daiichi Sankyo Co., Ltd., Tokyo, Japan., Garimella T; Quantitative Clinical Pharmacology, Daiichi Sankyo Inc., Basking Ridge, NJ, USA., Abutarif M; Quantitative Clinical Pharmacology, Daiichi Sankyo Inc., Basking Ridge, NJ, USA.

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2023 Nov; Vol. 63 (11), pp. 1232-1243. Date of Electronic Publication: 2023 Jul 12.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.

Autor: Yin O; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA., Iwata H; Aichi Cancer Center, Nagoya, Japan., Lin CC; National Taiwan University Hospital, Taipei, Taiwan., Tamura K; National Cancer Center Japan, Tokyo, Japan., Watanabe J; Shizuoka Cancer Center, Shizuoka, Japan., Wada R; Certara USA, Inc., Princeton, New Jersey, USA., Kastrissios H; Certara USA, Inc., Princeton, New Jersey, USA., AbuTarif M; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA., Garimella T; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA., Lee C; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA., Zhang L; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA., Shahidi J; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA., LaCreta F; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Oct; Vol. 110 (4), pp. 986-996. Date of Electronic Publication: 2021 Jun 10.

Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia.

Autor: Kang D; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA. dkang@dsi.com., Ludwig E; Cognigen Corporation, a Simulations Plus Company, Buffalo, NY, USA., Jaworowicz D; Cognigen Corporation, a Simulations Plus Company, Buffalo, NY, USA., Huang H; Cognigen Corporation, a Simulations Plus Company, Buffalo, NY, USA., Fiedler-Kelly J; Cognigen Corporation, a Simulations Plus Company, Buffalo, NY, USA., Cortes J; Georgia Cancer Center at Augusta University, Augusta, GA, USA., Ganguly S; University of Kansas Cancer Center, Fairway, KS, USA., Khaled S; City of Hope, Arcadia, CA, USA., Krämer A; Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Levis M; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA., Martinelli G; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy., Perl A; Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Russell N; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK., Abutarif M; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Choi Y; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Yin O; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 Apr; Vol. 87 (4), pp. 513-523. Date of Electronic Publication: 2021 Jan 08.